Urgent: Measles Outbreaks Put Vulnerable Rheumatic Patients at Risk
Ongoing measles outbreaks are creating serious infection risks for adults with autoimmune rheumatic diseases, particularly in communities where pediatric vaccination rates have fallen below protective levels. Measles is highly contagious; controlling transmission generally requires about 95% population immunity. When coverage slips under that threshold, people whose immune systems are dysregulated or suppressed by treatment face heightened exposure and greater risk of severe illness.
Clinicians caring for these patients must assess measles immunity before making vaccination decisions. The measles, mumps, and rubella (MMR) vaccine is a live-attenuated formulation given as a two-dose series at least four weeks apart and reliably protects immunocompetent individuals. However, live vaccines are contraindicated for patients actively receiving conventional synthetic, targeted synthetic, or biologic disease‑modifying antirheumatic drugs (DMARDs) because vaccine virus can produce viremia that may persist for up to four weeks in immunosuppressed hosts.
Current guidance calls for tailored interruptions of immunosuppressive therapy when unimmunized patients need measles protection. Methotrexate, leflunomide and systemic glucocorticoids are typically withheld for four weeks before vaccination. Janus kinase (JAK) inhibitors are paused for one week. B‑cell–depleting agents such as rituximab require a longer delay-commonly about six months-while other biologics are held for one dosing interval. After receiving the MMR vaccine, antirheumatic treatments are generally withheld for an additional four weeks to allow viral clearance and antibody formation.
Emerging data offer some reassurance: recent trials of CD19‑directed CAR T‑cell therapy in refractory autoimmune disease reported preserved measles antibody titers after treatment. Still, clinicians must carefully balance the immediate infection risks posed by measles against the danger of autoimmune flare when interrupting therapy. These recommendations and observations are discussed in a 2026 review by Kapetanovic in Nature Reviews Rheumatology.
Original Source: https://www.emjreviews.com/rheumatology/news/measles-outbreaks-threaten-vulnerable-rheumatic-patients/
Category:
Tags:
Publish Date: 2026-09-14 23:29:00